Reviews the decade-long progress in EGFR-targeted therapies and introduces the rationale for first-line dual inhibition.
Mechanisms of Acquired Resistance to First-Line Amivantamab Plus Lazertinib Vs Osimertinib: Updated Analysis from MARIPOSA
Illustrates how osimertinib resistance emerges through diverse EGFR and MET alterations, leading to disease relapse.
Presents MARIPOSA trial results showing superior progression-free survival and overall survival with amivantamab plus lazertinib.
Advertisement
Advertisement
Trending on CancerNetwork
1
Atezolizumab/Vaccine Combo May Show Long-Term Survival in ES-SCLC
2
FDA Accepts New Drug Application for 177Lu-Edotreotide in GEP-NETs
3
PEF Ablation Yields Local Control, May Elicit Immune Response in Solid Tumors
4
Identifying Common Toxicities with Targeted Therapies in GI Malignancies
5
